Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFP and Rituximab in Advanced Refractory CLL
NCT00892827Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 2009
- Primary completion
- Jul 2009
- Countries
- 1
- Sponsor
- Edith Wolfson Medical Center
- Modality
- Monoclonal Antibodies
- Drugs
- rituximab
- Conditions
- chronic lymphocytic leukemia (CLL)
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia (CLL), sponsored by Edith Wolfson Medical Center. Primary endpoint: Complete/Partial Response Rate at 3 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Rituximab + FFP
Rituximab (375 mg/m2) + Fresh Frozen Plasma (2 units)
03
Who it enrols
Patients with advanced refractory CLL (Rai stage >=2 or symptomatic stage 1) resistant to Fludarabine/Rituximab, with high lymphocyte counts (>= 100,000/mcl).
04
Endpoints
Primary
Complete/Partial Response Rate
Secondary
Time to Disease Progression
Time to Re-treatment
Safety of Combination Treatment
Beyond the preview
Go deeper on NCT00892827.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00892827.